These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16085235)

  • 1. Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
    Idvall I; Ringberg A; Anderson H; Akerman M; Fernö M
    Breast; 2005 Aug; 14(4):290-7. PubMed ID: 16085235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study.
    Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
    Pathology; 2004 Jun; 36(3):221-9. PubMed ID: 15203725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI; Malone KE; Saltzman BS; Daling JR
    Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
    Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R
    Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity.
    Smeds J; Wärnberg F; Norberg T; Nordgren H; Holmberg L; Bergh J
    Acta Oncol; 2005; 44(1):41-9. PubMed ID: 15848905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast.
    Ringberg A; Idvall I; Fernö M; Anderson H; Anagnostaki L; Boiesen P; Bondesson L; Holm E; Johansson S; Lindholm K; Ljungberg O; Ostberg G
    Eur J Surg Oncol; 2000 Aug; 26(5):444-51. PubMed ID: 11016463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast.
    Lee LA; Silverstein MJ; Chung CT; Macdonald H; Sanghavi P; Epstein M; Holmes DR; Silberman H; Ye W; Lagios MD
    Am J Surg; 2006 Oct; 192(4):416-9. PubMed ID: 16978940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age.
    Schouten van der Velden AP; Peeters PH; Koot VC; Hennipman A
    Ann Surg Oncol; 2006 Jul; 13(7):990-8. PubMed ID: 16788762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
    Sanders ME; Schuyler PA; Dupont WD; Page DL
    Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bilateral ductal carcinoma in situ of the breast: independent events or bilateral disease?].
    André G; Tunon-de-Lara C; Macgrogan G; Laharie-Mineur H; Bussieres JE; Valentin F; Barreau B; Dilhuydy MH; Dilhuydy JM; Mauriac L; Debled M; Durand M; Mathoulin S; Avril A
    J Gynecol Obstet Biol Reprod (Paris); 2007 May; 36(3):260-6. PubMed ID: 17376610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
    Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
    Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
    Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M
    Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of ductal carcinoma in situ (DCIS) of the breast].
    Westenberg AH; Rutgers EJ; Peterse JL; Hendriks JH; Beex LV; van Tienhoven G
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2157-61. PubMed ID: 14626831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
    Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.